67056 Ludwigshafen, de
+41 (27) 7661-606
Pharmaceutical excipient for instant-release tablet coatings approved in USA
FDA authorizes use of Kollicoat® IR
"Kollicoat IR allows manufacturers to benefit from more robust, much shorter production processes, which means they end up saving costs as well", says Inge Rademacher, product manager responsible for the excipient at BASF. The reason is that Kollicoat IR dissolves exceptionally rapidly and well in water. Because of its low viscosity, the Kollicoat IR solution can be sprayed on to the tablets with a high polymer and color pigment content. Film coatings based on Kollicoat IR are also extremely flexible and do not require additional plasticizers. The considerable disadvantages of using conventional polymers are now a thing of the past.
"But in addition to having advantages for the manufacturer, Kollicoat IR also benefits the patient," continues Inge Rademacher. For example, a particular film coating of the Kollicoat IR range masks the bitter taste or unpleasant odor of active pharmaceutical ingredients. Kollicoat IR also ensures that the tablets are much more convenient to take, because Kollicoat IR-coated tablets have a very smooth surface that makes them much easier to swallow.
Medicinal products containing Kollicoat IR have been approved in Germany since 2005 and in France, the UK, Spain and Portugal since May 2007. A draft monograph for the European Pharmacopoeia will appear in PharmEuropa Vol. 20/3 2008. Kollicoat IR has been registered in Japan since August 2007.
Kollicoat IR is manufactured by BASF in Germany according to cGMP guidelines and marketed worldwide.
About the business unit Pharma Ingredients & Services BASF produces and markets a broad range of active ingredients and excipients, as well as exclusive synthesis services for the pharmaceutical industry. These products are made using the latest technologies, to the highest quality standards and in compliance with cGMP guidelines.
Further information can be found at. www.pharma-ingredients.basf.com
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.